1:
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J.
Arthritis Res Ther. 2005;7(3):R439-44. Epub 2005 Feb 21. Erratum in: Arthritis Res Ther. 2005;7(3):113. Zink, Angela [added];Alten, Rieke [added]; Burmester, Gerd [added]; Gromnica-Ihle, Erika [added]; Kellner, Herbert [added]; Schneider, Matthias [added]; Sörensen, Helmut [added]; Zeidler, Henning [added]; Rudwaleit, Martin [added].
PMID: 15899030 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
2:
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sörensen H, Zeidler H, Visvanathan S, Sieper J, Braun J.
J Rheumatol. 2007 Mar;34(3):510-5. Epub 2007 Feb 1.
PMID: 17299842 [PubMed - indexed for MEDLINE]
Related Articles
4:
Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J.
Ann Rheum Dis. 2008 Mar;67(3):340-5. Epub 2007 Oct 29.
PMID: 17967831 [PubMed - indexed for MEDLINE]
Related Articles
5:
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
Rheumatology (Oxford). 2005 May;44(5):670-6. Epub 2005 Mar 9.
PMID: 15757965 [PubMed - indexed for MEDLINE]
Related Articles
6:
Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study.
Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, Euller-Ziegler L, Sibilia J, Perdriger A, Mezières M, Alexandre C, Dougados M.
Rheumatology (Oxford). 2002 Nov;41(11):1280-5.
PMID: 12422001 [PubMed - indexed for MEDLINE]
Related Articles
12:
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J.
Arthritis Rheum. 2003 Aug;48(8):2224-33.
PMID: 12905476 [PubMed - indexed for MEDLINE]
Related Articles
15:
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
Ann Rheum Dis. 2005 Feb;64(2):229-34. Epub 2004 Sep 23.
PMID: 15388511 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
20:
Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment.
Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, Euller-Ziegler L, Pham T, Solau-Gervais E, Chary-Valckenaere I, Marcelli C, Perdriger A, Le Loët X, Wendling D, Fautrel B, Fournié B, Combe B, Gaudin P, Jousse S, Mariette X, Baleydier A, Trape G, Dougados M; French Ankylosing Spondylitis Infliximab Network.
Arthritis Rheum. 2008 Jan;58(1):88-97.
PMID: 18163509 [PubMed - indexed for MEDLINE]
Related Articles